Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
about
Combination Therapy for Chronic Hepatitis B: Current IndicationsSystematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and BKushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-AnalysisManagement of chronic hepatitis B infection: current treatment guidelines, challenges, and new developmentsThe importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysisPrevention of hepatocellular carcinoma in patients with chronic hepatitis BNew virologic tools for management of chronic hepatitis B and CThe hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymesComparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysisCost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in ChinaCost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation.The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients.Evaluation of inconsistency in networks of interventionsKinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis BSequences in the terminal protein and reverse transcriptase domains of the hepatitis B virus polymerase contribute to RNA binding and encapsidationHepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanismsChronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practiceComparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis.Antiviral treatment among pregnant women with chronic hepatitis B.Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysisA cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in ItalyTenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patientsThe hepatitis B virus ribonuclease H as a drug targetHow further suppression of virus replication could improve current HBV treatment.Tenofovir-based alternate therapies for chronic hepatitis B patients with partial virological response to entecavir.Therapy for HBV Infection in Hemodialysis Patients: Is it Possible?Application of Bayesian Approach to Cost-Effectiveness Analysis of Antiviral Treatments in Chronic Hepatitis B.The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic reviewDisease burden of chronic hepatitis B among immigrants in Canada.Tenofovir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series.Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B.Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection.A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model.Comparative evaluation of long-term monotherapies & combination therapies in patients with chronic hepatitis B: A pilot study.Pediatric hepatitis B treatment.Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
P2860
Q24604492-C22E8DA7-4344-4856-9B5E-A7B14963D31BQ26777916-4632A272-C033-4656-BEE1-60AA7CF777BBQ26782748-8382DAAA-302F-4945-AFFD-FA71DD506CDBQ27008984-BA5AF300-47CE-4EBB-A35D-088107E7E584Q27016075-100FACAA-DF3B-45E6-AA1D-45583F04B4E6Q27023997-561663D7-4572-4749-BA23-4F53C28D57BEQ27026914-CE788FF5-B641-4D5F-BDA5-B1A0E858A329Q28485228-1E656BF6-6505-4F34-990A-ED17400EE26CQ28539472-C2AA4524-060C-4C93-9ED2-72399C454A22Q28550643-9FD1FF7E-8D73-483E-954B-08025D9BF00DQ30368481-72FD31F6-135F-4732-9D0C-09DAE62AEB50Q30586377-DA04464E-3F72-46CE-AC31-A07A4C9BA72CQ33620679-7E811392-B919-41E8-9860-AEAD52ACA677Q33721394-B6C7B83E-EC43-4353-AB75-E8C141D82FD3Q33875691-287A9D46-2A30-4F80-B6AC-9A76FC85AF52Q33911464-BFF18BAE-DB06-4FAA-AB6E-251482ECB574Q34107343-CBFC8779-9F81-4714-930F-CA8984C11725Q34256062-4A7AF24A-77EB-4A82-9BFA-35B0B2A6DE95Q34623662-59FA8E01-BF95-4174-92A8-7A53AB184AB6Q34762578-9473FFD4-7031-426E-A558-709ACEB9A01FQ34847029-E25FF8C9-3874-4B78-966D-C15A427D0C85Q35205440-58C8A37A-46F5-456B-8D2C-CD4E6469425BQ35231822-75603847-2A47-443D-8C9E-D55A10B4CB76Q35582561-F78FDFB4-BFDA-4863-BC61-6439B84CF0F0Q35622347-F97AF4F7-BE4F-4116-A680-9CB6E19F2DB3Q35639847-9D0E8588-3147-4D6B-A96F-8C93A02A9760Q35920128-986C61FA-B794-4191-84B1-C9D05FF2607CQ36116667-0A8A9BD5-0670-425E-9FDF-3CBE2E7F3D68Q36189795-B97871CF-DE05-46BA-A601-7B5AFF5AB586Q37029967-AF6724A4-4620-4692-BDB9-351AD71780FBQ37066397-DD8AB7DF-437E-4E8E-9310-9B9300ACA167Q37137734-CF268555-1162-44DB-866D-A35DA1237B8DQ37200146-ABF726F1-3A24-4431-A731-41D0D40BDBE8Q37217853-DDA264A2-5FB4-4D01-8DD9-8484E3006713Q37335661-AA94F9C6-78DE-4444-86A9-5BCCC8BA17DEQ37387494-6C0450FD-4176-4BB8-A336-18BEC14B33C7Q37658659-0FD751F4-C8C1-4DCA-8CDB-3AF6B8D3F3E5Q37666967-B359C968-086B-4C2E-BE36-CDB20602925CQ37722853-697D4656-CB30-4B90-9212-1B2C8E20E6DEQ37825532-07181455-92C9-4D5C-8C86-33323C72BE3B
P2860
Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Tenofovir and entecavir are th ...... ew and Bayesian meta-analyses.
@ast
Tenofovir and entecavir are th ...... ew and Bayesian meta-analyses.
@en
Tenofovir and entecavir are th ...... ew and Bayesian meta-analyses.
@nl
type
label
Tenofovir and entecavir are th ...... ew and Bayesian meta-analyses.
@ast
Tenofovir and entecavir are th ...... ew and Bayesian meta-analyses.
@en
Tenofovir and entecavir are th ...... ew and Bayesian meta-analyses.
@nl
prefLabel
Tenofovir and entecavir are th ...... ew and Bayesian meta-analyses.
@ast
Tenofovir and entecavir are th ...... ew and Bayesian meta-analyses.
@en
Tenofovir and entecavir are th ...... ew and Bayesian meta-analyses.
@nl
P2093
P50
P1433
P1476
Tenofovir and entecavir are th ...... iew and Bayesian meta-analyses
@en
P2093
E Jenny Heathcote
Gloria Woo
Matthew Kowgier
Morris Sherman
Thomas R Einarson
Wendy J Ungar
Yasunori Nishikawa
P304
P356
10.1053/J.GASTRO.2010.06.042
P407
P577
2010-06-20T00:00:00Z